• Overview
  • Eligibility
  • More info
  • Locations

High-Dose Infusional Taxol, Amifostine, Doxorubicin, and Cyclophosphamide Followed by Stem Cell Rescue for High Risk Primary and Responsive Metastatic Breast Cancer (NCT00003927)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Amifostine may protect normal cells from the side effects of chemotherapy. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy, amifostine, and peripheral stem cell transplantation in treating patients who have stage II, stage III, or stage IV breast cancer.
  • Biological: filgrastim
    • Drug: amifostine trihydrate
      • Drug: cyclophosphamide
        • Drug: doxorubicin hydrochloride
          • Drug: paclitaxel
            • Procedure: peripheral blood stem cell transplantation
              Ages eligible for Study
              18 Years to 59 Years
              Genders eligible for Study
              Accepts Healthy Volunteers
              OBJECTIVES: I. Evaluate the feasibility of high dose doxorubicin, cyclophosphamide, paclitaxel, and amifostine in patients with high risk stage II/III and responsive stage IV advanced breast cancer. II. Determine the pharmacokinetic profile of paclitaxel administered with amifostine in this regimen in these patients. III. Assess the toxicity of this treatment regimen in this patient population.

              OUTLINE: Patients receive filgrastim (G-CSF) subcutaneously twice daily on days 1-4 for peripheral blood stem cell (PBSC) mobilization and continuing through days 5-10 during PBSC collection. At least 2 weeks following mobilization, patients receive doxorubicin IV as a continuous infusion on days -9 through -5 followed by cyclophosphamide IV over 2 hours on day -5 and amifostine IV over 15 minutes, and paclitaxel IV over 24 hours on day -4. On day -2, 25% PBSC are reinfused and 75% are reinfused on day 0, followed by daily G-CSF subcutaneously or IV beginning on day 1. Patients are followed every 3 months for 2 years, then periodically thereafter.

              PROJECTED ACCRUAL: A total of 15 patients will be accrued for this study within 6-8 months.

              1 locations

              United States (1)
              • Cancer Center and Beckman Research Institute, City of Hope
                Not specified
                Duarte, California, United States, 91010-3000
              active not recruiting
              21 April, 1999
              23 April, 2017
              A girl giving information about available additional trials.

              FindMeCure helps you find, understand and join clinical trials from all over the world.

              There are more clinical trials for your condition!